Biopharma layoffs and projected cuts moderated year over year in Q1 2026, but total affected employees rose. Reporting from BioSpace indicates 35 companies made or planned cuts in Q1 2026 versus 74 in Q1 2025, while employee counts increased due largely to a sizable Viatris restructuring. Viatris plans to reduce up to 10% of its global workforce over three years, which could affect roughly 3,000 roles. Evotec’s strategic reorganization is also cited as a major driver, with potential job reductions as the company downsizes its global site footprint. The mixed picture suggests that funding uncertainty has eased compared with last year, but cost and footprint rationalization continues to reshape headcount across the sector.